UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

The New England journal of medicine, 2016-01, Vol.374 (1), p.54-61

2016

Link zum Volltext

Verfügbarkeit prüfen

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Proceedings of the National Academy of Sciences - PNAS, 2015-03, Vol.112 (11), p.3493-3498

2015

Link zum Volltext

Verfügbarkeit prüfen

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

Cancer discovery, 2016-01, Vol.6 (1), p.96-107

2016

Link zum Volltext

Verfügbarkeit prüfen

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth

Proceedings of the National Academy of Sciences - PNAS, 2010-05, Vol.107 (20), p.9446-9451

2010

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies

Pigment cell and melanoma research, 2012-11, Vol.25 (6), p.819-831

2012

Link zum Volltext

Verfügbarkeit prüfen

Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)

Scientific reports, 2017-08, Vol.7 (1), p.7305-13, Article 7305

2017

Link zum Volltext

Verfügbarkeit prüfen

Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1

The Journal of pharmacology and experimental therapeutics, 2014-10, Vol.351 (1), p.67

2014

Link zum Volltext

Verfügbarkeit prüfen

Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase

Drug metabolism and disposition, 2015-01, Vol.43 (1), p.54-62

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia

Journal of hematology and oncology, 2017-05, Vol.10 (1), p.112-112, Article 112

2017

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor

Molecular cancer therapeutics, 2012-04, Vol.11 (4), p.1036-1047

2012

Link zum Volltext

Verfügbarkeit prüfen

PAK4 mediates morphological changes through the regulation of GEF-H1

Journal of cell science, 2005-05, Vol.118 (9), p.1861-1872

2005

Link zum Volltext

Verfügbarkeit prüfen

Requirement for PAK4 in the Anchorage-independent Growth of Human Cancer Cell Lines

The Journal of biological chemistry, 2002-01, Vol.277 (1), p.550-558

2002

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Pyrroloaminopyrazoles as Novel PAK Inhibitors

Journal of medicinal chemistry, 2012-05, Vol.55 (10), p.4728-4739

2012

Link zum Volltext

Verfügbarkeit prüfen

Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells

PloS one, 2012-10, Vol.7 (10), p.e48402

2012

Link zum Volltext

Verfügbarkeit prüfen

The Serine/Threonine Kinase Nek6 Is Required for Cell Cycle Progression through Mitosis

The Journal of biological chemistry, 2003-12, Vol.278 (52), p.52454-52460

2003

Link zum Volltext

Verfügbarkeit prüfen

Control of transcription factors by signal transduction pathways: the beginning of the end

Trends in biochemical sciences (Amsterdam. Regular ed.), 1992-10, Vol.17 (10), p.418-422

1992

Link zum Volltext

Verfügbarkeit prüfen

Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain

Nature (London), 1991-05, Vol.351 (6322), p.122-127

1991

Link zum Volltext

Verfügbarkeit prüfen

The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1

Cell, 1988-12, Vol.55 (5), p.875-885

1988

Link zum Volltext

Verfügbarkeit prüfen

Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction

Cell, 1990-09, Vol.62 (6), p.1205-1215

1990

Link zum Volltext

Verfügbarkeit prüfen

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations

Journal of medicinal chemistry, 2014-06, Vol.57 (11), p.4720-4744

2014

Link zum Volltext

Verfügbarkeit prüfen

Casein kinase II is a negative regulator of c-Jun DNA binding and AP-1 activity

Cell, 1992-09, Vol.70 (5), p.777-789

1992

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design

Molecular cancer therapeutics, 2010-06, Vol.9 (6), p.1618-1628

2010

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 1‑{(3R,4R)‑3-[({5-Chloro-2-[(1-methyl‑1H‑pyrazol-4-yl)amino]‑7H‑pyrrolo[2,3‑d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants

Journal of medicinal chemistry, 2016-03, Vol.59 (5), p.2005-2024

2016

Link zum Volltext

Verfügbarkeit prüfen

Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target

Molecular cancer research, 2010-05, Vol.8 (5), p.717-728

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(77)

Sprache

Englisch
(77)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(35)
Humans
(34)
Animals
(25)
Cell Biology
(17)
Mice
(17)
Phosphorylation
(14)
Biochemistry & Molecular Biology
(13)
Cell Line, Tumor
(13)
Mutation
(13)
Biological And Medical Sciences
(12)
Oncology
(12)
Protein Kinase Inhibitors - Pharmacology
(12)
Antineoplastic Agents - Pharmacology
(11)
Fundamental And Applied Biological Sciences. Psychology
(9)
Molecular And Cellular Biology
(9)
Xenograft Model Antitumor Assays
(9)
Amino Acid Sequence
(8)
Female
(8)
Molecular Sequence Data
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth

Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies

Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)

Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1

Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia

Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor

PAK4 mediates morphological changes through the regulation of GEF-H1

Requirement for PAK4 in the Anchorage-independent Growth of Human Cancer Cell Lines

Discovery of Pyrroloaminopyrazoles as Novel PAK Inhibitors

Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells

The Serine/Threonine Kinase Nek6 Is Required for Cell Cycle Progression through Mitosis

Control of transcription factors by signal transduction pathways: the beginning of the end

Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain

The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1

Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction

Casein kinase II is a negative regulator of c-Jun DNA binding and AP-1 activity

Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design

Discovery of 1‑{(3R,4R)‑3-[({5-Chloro-2-[(1-methyl‑1H‑pyrazol-4-yl)amino]‑7H‑pyrrolo[2,3‑d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants

Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target

Suchergebnisse filtern